Archive

HIGHLIGHTS

 
LSP leads $180 million Series A Financing in Newly-Formed Arvelle Therapeutics
LSP leads one of the largest initial financings for a European biotech company in a global syndicate supporting Arvelle to acquire exclusive rights from SK Biopharmaceuticals to develop and commercialize Cenobamate in[...]
 
LSP raises record €750 million in 10 months for life sciences innovations
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY JURISDICTION IN WHICH TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   Succe[...]
 
LSP leads €28 million Series B financing in Atlantic Therapeutics
Amsterdam, the Netherlands, January 7, 2019 – LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investment in Atlantic Therapeutics, the Irish medical technology company deve[...]
 
LSP leads $28 million financing in Lumeon
Amsterdam, the Netherlands, December 4, 2018 – LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investment in Lumeon, a digital health company and leader in the field of[...]
 
LSP co-leads $85 million (£65 million) Series B Financing in Artios Pharma
LSP returns to support the former KuDOS team that successfully developed the first PARP inhibitor Olaparib   Amsterdam, The Netherlands, August 10, 2018 – LSP, Europe’s leading life sciences investor, tod[...]
 
LSP wins Lifestars Award for EU investment firm of the year
Celebrating success across life sciences   Amsterdam, The Netherlands, November 14, 2018 – LSP is pleased to announce that it has been recognised as the winner of the EU Investment Firm of the year at the 2[...]
 
LSP leads $45 million Series D Financing in Endotronix
Amsterdam, the Netherlands, September 17, 2018 – LSP, Europe’s leading life sciences investor, today announced its investment in Endotronix, Inc., a digital health, medtech company dedicated to advancing the treat[...]
 
LSP's portfolio company GTX Medical on Dokters van Morgen
Dutch TV program 'Dokters van Morgen' reporting on new revolutionary ways to treat spinal cord injuries. From Minute 19 - 35, you can see LSP porfolio company GTX Medical founder Grégoire Courtine giving insi[...]
 
LSP IN THE NEWS
LSP on BNR by Marco Groot (around Minute 3:00)
 
Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser and René Kuijten
Oncode Institute combines 600 of the very best oncology researchers with a highly qualified valorisation staff to ensure that breakthrough discoveries get to patients faster.    The origins of Oncode go back[...]
 
LSP Raises EUR 280 Million to Invest In Healthcare Innovation
Largest fund in Europe dedicated to medical technology Significant fundraise reflects successful investment strategy to achieve better care at lower costs   Amsterdam, 12 December 2017 – LSP, the Europe[...]
 
Marco Groot over LSP in het FD
Amsterdam, April 11, 2017 Marco Groot over LSP in het FD Lees de gehele column: Een absoluut beter resultaat   Amsterdam, July 11, 2017: Marco Groot blikt in het FD terug op zijn eerdere positiev[...]
 
Is a cure for cancer finally within reach?
To read the full article click here

2019


LSP leads $180 million Series A Financing in Newly-Formed Arvelle Therapeutics
LSP leads one of the largest initial financings for a European biotech company in a global syndicate supporting Arvelle to acquire exclusive rights from SK Biopharmaceuticals to develop and commercialize Cenobamate in [...]
Kuros Biosciences signs agreement to supply SeaSpine with bone graft incorporating Kuros’s advanced submicron surface technology
Global partner to market an advanced bone graft supplied by Kuros Agreement demonstrates interest of major orthobiologic companies in Kuros technologies   Schlieren (Zurich), Switzerland, February [...]
argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology
argenx gains access to ENHANZE® subcutaneous delivery technology for up to three targets, including exclusive rights to develop therapeutic products targeting human neonatal Fc receptor FcRn Breda, the N [...]
LSP's portfolio company GTX Medical on “Dokters van Morgen”
Dutch TV program 'Dokters van Morgen' reporting on new revolutionary ways to treat spinal cord injuries. From Minute 19 - 35, you can see LSP porfolio company GTX Medical founder Grégoire Courtine giving insi [...]
Orphazyme reports positive results from full data set of Phase II/III arimoclomol trial in Niemann-Pick disease Type C (NPC)
Primary endpoint shows 74% reduction in disease progression after 12 months compared to placebo control (p-value =0.0506) Biomarker results demonstrate statistically significant biological response to treatm [...]
Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company
Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets – Lead Program, IMU-838, an Orally [...]


2019
2018
2017
2016
2015
2014
2013
2012
back to news overview
Follow us

Archive

HIGHLIGHTS

 
LSP leads $180 million Series A Financing in Newly-Formed Arvelle Therapeutics
LSP leads one of the largest initial financings for a European biotech company in a global syndicate supporting Arvelle to acquire exclusive rights from SK Biopharmaceuticals to develop and commercialize Cenobamate in[...]
 
LSP raises record €750 million in 10 months for life sciences innovations
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY JURISDICTION IN WHICH TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   Succe[...]
 
LSP leads €28 million Series B financing in Atlantic Therapeutics
Amsterdam, the Netherlands, January 7, 2019 – LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investment in Atlantic Therapeutics, the Irish medical technology company deve[...]
 
LSP leads $28 million financing in Lumeon
Amsterdam, the Netherlands, December 4, 2018 – LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investment in Lumeon, a digital health company and leader in the field of[...]
 
LSP co-leads $85 million (£65 million) Series B Financing in Artios Pharma
LSP returns to support the former KuDOS team that successfully developed the first PARP inhibitor Olaparib   Amsterdam, The Netherlands, August 10, 2018 – LSP, Europe’s leading life sciences investor, tod[...]
 
LSP wins Lifestars Award for EU investment firm of the year
Celebrating success across life sciences   Amsterdam, The Netherlands, November 14, 2018 – LSP is pleased to announce that it has been recognised as the winner of the EU Investment Firm of the year at the 2[...]
 
LSP leads $45 million Series D Financing in Endotronix
Amsterdam, the Netherlands, September 17, 2018 – LSP, Europe’s leading life sciences investor, today announced its investment in Endotronix, Inc., a digital health, medtech company dedicated to advancing the treat[...]
 
LSP's portfolio company GTX Medical on “Dokters van Morgen”
Dutch TV program 'Dokters van Morgen' reporting on new revolutionary ways to treat spinal cord injuries. From Minute 19 - 35, you can see LSP porfolio company GTX Medical founder Grégoire Courtine giving insi[...]
 
LSP IN THE NEWS
LSP on BNR by Marco Groot (around Minute 3:00)
 
Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser and René Kuijten
Oncode Institute combines 600 of the very best oncology researchers with a highly qualified valorisation staff to ensure that breakthrough discoveries get to patients faster.    The origins of Oncode go back[...]
 
LSP Raises EUR 280 Million to Invest In Healthcare Innovation
Largest fund in Europe dedicated to medical technology Significant fundraise reflects successful investment strategy to achieve better care at lower costs   Amsterdam, 12 December 2017 – LSP, the Europe[...]
 
Marco Groot over LSP in het FD
Amsterdam, April 11, 2017 Marco Groot over LSP in het FD Lees de gehele column: Een absoluut beter resultaat   Amsterdam, July 11, 2017: Marco Groot blikt in het FD terug op zijn eerdere positiev[...]
 
Is a cure for cancer finally within reach?
To read the full article click here

2019


LSP leads $180 million Series A Financing in Newly-Formed Arvelle Therapeutics
LSP leads one of the largest initial financings for a European biotech company in a global syndicate supporting Arvelle to acquire exclusive rights from SK Biopharmaceuticals to develop and commercialize Cenobamate in [...]
Kuros Biosciences signs agreement to supply SeaSpine with bone graft incorporating Kuros’s advanced submicron surface technology
Global partner to market an advanced bone graft supplied by Kuros Agreement demonstrates interest of major orthobiologic companies in Kuros technologies   Schlieren (Zurich), Switzerland, February [...]
argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology
argenx gains access to ENHANZE® subcutaneous delivery technology for up to three targets, including exclusive rights to develop therapeutic products targeting human neonatal Fc receptor FcRn Breda, the N [...]
LSP's portfolio company GTX Medical on “Dokters van Morgen”
Dutch TV program 'Dokters van Morgen' reporting on new revolutionary ways to treat spinal cord injuries. From Minute 19 - 35, you can see LSP porfolio company GTX Medical founder Grégoire Courtine giving insi [...]
Orphazyme reports positive results from full data set of Phase II/III arimoclomol trial in Niemann-Pick disease Type C (NPC)
Primary endpoint shows 74% reduction in disease progression after 12 months compared to placebo control (p-value =0.0506) Biomarker results demonstrate statistically significant biological response to treatm [...]
Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company
Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets – Lead Program, IMU-838, an Orally [...]


2019
2018
2017
2016
2015
2014
2013
2012
back to news overview